Francomano D, Ilacqua A, Cortese A, Tartaglia G, Lenzi A, Inghilleri M, Aversa A
Department of Experimental Medicine, Endocrinology and Food and Science Section, Sapienza University of Rome, Rome, Italy.
Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy.
J Endocrinol Invest. 2017 Mar;40(3):275-279. doi: 10.1007/s40618-016-0557-y. Epub 2016 Oct 17.
Men affected by multiple sclerosis often experience neurogenic overactive bladder (OAB), lower urinary tract symptoms and erectile dysfunction (ED). The aim of the study was to investigate modifications of urinary and sexual functions after administration of daily tadalafil (TAD) 5 mg.
Twenty men were enrolled in a single-blind, 4-week prospective study while 10 men without treatment served as controls. Primary outcomes were changes from baseline of International Prostate Symptom (IPSS), OAB questionnaire (OAB-q-short form) and International Index of Erectile Function (IIEF-5) scores. To evaluate the influence of bladder filling on somatic reflexes, we studied variations of the H-reflex evoked by electrical stimuli applied to the tibial nerve at the popliteal fossa and recorded from the soleus muscle. Also testosterone/estradiol (T/E) ratio was measured before and after treatment.
In TAD group, an improvement in IPSS (p < 0.001), OAB-q (p < 0.001) and IIEF-5 (p < 0.001) scores was found. Also, an increase in Q (p < 0.01) and T/E ratio (p < 0.01) was found with a concomitant reduction in post-void residual volume (p < 0.001) without any changes in the H-reflex.
The study demonstrates for the first time that daily TAD in patients with multiple sclerosis improves storage symptoms, post-void residual volume, steroid hormone pattern and ED without urodynamic changes.
患有多发性硬化症的男性常经历神经源性膀胱过度活动症(OAB)、下尿路症状和勃起功能障碍(ED)。本研究的目的是调查每日服用5毫克他达拉非(TAD)后泌尿和性功能的变化。
20名男性参与了一项单盲、为期4周的前瞻性研究,同时10名未接受治疗的男性作为对照。主要结局指标是国际前列腺症状评分(IPSS)、OAB问卷(OAB-q简表)和国际勃起功能指数(IIEF-5)得分相对于基线的变化。为了评估膀胱充盈对躯体反射的影响,我们研究了在腘窝处对胫神经施加电刺激并从比目鱼肌记录的H反射的变化。同时还测量了治疗前后的睾酮/雌二醇(T/E)比值。
在TAD组中,发现IPSS(p < 0.001)、OAB-q(p < 0.001)和IIEF-5(p < 0.001)得分有所改善。此外,发现Q(p < 0.01)和T/E比值增加(p < 0.01),同时排尿后残余尿量减少(p < 0.001),而H反射无任何变化。
该研究首次表明,多发性硬化症患者每日服用TAD可改善储尿症状、排尿后残余尿量、类固醇激素模式和ED,且不伴有尿动力学变化。